NPPB and congestive heart failure: The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which divided HF patients into two groups: 523 [LVEF] < 40% and 662 LVEF ≥ 40%, noted that elevated NLR was significantly correlated with worse outcome, inflammation-related biomarkers, and cardiac biomarkers such as NT-proBNP [25].